| Literature DB >> 27912738 |
Mohammad Raish1, Ajaz Ahmad2, Khalid M Alkharfy3, Syed Rizwan Ahamad4, Kazi Mohsin5, Fahad I Al-Jenoobi5, Abdullah M Al-Mohizea5, Mushtaq Ahmad Ansari6.
Abstract
BACKGROUND: Fulminant hepatic failure (FHF) is clinical syndrome with very poor prognosis and high mortality there is urgent need for the development of safe and non-toxic hepatoprotective agents for the adequate management of hepatitis. Hepatoprotective effect of the Lepidium sativum ethanolic extract (LSEE) was assessed by D-galactosamine-induced/lipopolysaccharide (400 mg/kg and 30 μg/kg) liver damage model in rats.Entities:
Keywords: Cytokines; D-galactosamine/lipopolysaccharide; Hepatotoxicity; Lepidium sativum
Mesh:
Substances:
Year: 2016 PMID: 27912738 PMCID: PMC5135812 DOI: 10.1186/s12906-016-1483-4
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Effect of Lepidium sativum extract on liver and oxidative stress markers in D-GalN/LPS–induced hepatotoxicity
| Serum | Control | D-GalN/LPS | Silymarin | D-GalN/LPS+ LSEE 150 mg/kg | D-GalN/LPS+ LSEE 300 mg/kg |
|---|---|---|---|---|---|
| AST U/L | 75.80 ± 1.04 | 213.52 ± 2.59 | 93.95 ± 0.86 | 194.28 ± 1.32 | 126.25 ± 1.62 |
| ALT U/L | 33.94 ± 0.98 | 95.96 ± 1.21 | 52.39 ± 1.20 | 82.93 ± 1.61 | 60.96 ± 1.56 |
| ALP U/L | 81.09 ± 1.80 | 180.86 ± 3.38 | 94.07 ± 2.03 | 150.10 ± 2.58 | 103.76 ± 1.30 |
| Bilurubine plasma mg/dL | 0.72 ± 0.01 | 1.01 ± 0.01 | 0.69 ± 0.01 | 0.92 ± 0.012 | 0.70 ± 0.01 |
| γ-GGT | 1.26 ± 0.06 | 3.12 ± 0.14 | 1.70 ± 0.04 | 2.49 ± 0.04 | 2.01 ± 0.08 |
| CAT U/mg | 45.09 ± 1.07 | 20.98 ± 1.06 | 39.63 ± 1.63 | 24.43 ± 1.22 | 34.18 ± 1.01 |
| GSH nmol/mg | 1.17 ± 0.02 | 0.46 ± 0.02 | 0.98 ± 0.02 | 0.71 ± 0.01 | 0.86 ± 0.02 |
| MDA nmol/minute/mg | 3.20 ± 0.10 | 9.80 ± 0.23 | 3.95 ± 0.16 | 7.60 ± 0.18 | 6.36 ± 0.14 |
| SOD U/mg protein | 22.24 ± 0.41 | 10.53 ± 0.35 | 20.49 ± 0.85 | 17.35 ± 0.60 | 19.57 ± 0.54 |
Data presented as mean ± SEM
Fig. 1Effect of Lepidium sativum extract on mRNA expression of cytokines genes such tumor necrotic factor-α (TNFα), Interluekine 6 (IL-6), and Interluekine 10 (IL-10). All values represent mean ± SEM. *p < 0.05; ANOVA, followed by Dunnett’s multiple comparision test. *compared to GalN/LPS only group
Fig. 2Effect of Lepidium sativum extract on mRNA expression of cytokines genes such nitrous oxide synthase (iNOS) and Haemoxygensae1 (HO-1). All values represent mean ± SEM. *p < 0.05; ANOVA, followed by Dunnett’s multiple comparision test. * compared to GalN/LPS only group
Fig. 3Effect of LSEE on D-GalN/LPS-induced changes in inflammatory and apoptotic markers in Liver tissues of rats. a Myeloperoxidase (MPO) (b) Nuclear NF-κB (p65) DNA-binding activity determined by using NF-κB (p65) transcription factor ELISA assay kit. c Immunoblot analysis of apoptotic marker cleaved caspase-3 and antiapoptotic marker Bcl-2 protein in comparison with β-actin expression was used as a loading control. All values represent mean ± SEM. *p < 0.05; ANOVA, followed by Dunnett’s multiple comparision test. * compared to GalN/LPS only group
Fig. 4Histopathology of liver tissues. a Liver section of normal control rat shows central vein surrounded by hepatic cord of cells (normal architecture), b liver section of D-GalN/LPS treated rats showing massive fatty changes, focal central vein congestion, ballooning formation, necrosis with inflammation and loss of cellular boundaries, c liver section of rats treated D-GalN/LPS and 150 mg/kg of LSEE showing mild central vein congestion (indicated by arrow), ballooning, necrosis with sinusoidal dilatation, d liver section of rats treated D-GalN/LPS and 300 mg/kg of LSEE showing absence of ballooning, inflammatory cells and regeneration of hepatocytes around central vein toward near normal liver architecture but slight congestion in central vein (indicated by arrow), e liver section of rats treated D-GalN/LPS and 10 mg/kg of silymarin showing normal liver architecture